The frequency of late-onset Pompe disease in pediatric patients with limb-girdle muscle weakness and nonspecific hyperCKemia: A multicenter study

dc.authorid0000-0002-3724-7416
dc.authorid0000-0002-6607-5860
dc.authorid0000-0002-3613-0814
dc.authorid0000-0002-6749-5795
dc.contributor.authorUnver, Olcay
dc.contributor.authorHacifazlioglu, Nilufer Eldes
dc.contributor.authorKaratoprak, Elif
dc.contributor.authorGunes, Ayfer Sakarya
dc.contributor.authorSager, Gunes
dc.contributor.authorKutlubay, Busra
dc.contributor.authorSozen, Gulhan
dc.date.accessioned2025-05-10T19:43:11Z
dc.date.issued2016
dc.departmentİstanbul Medeniyet Üniversitesi
dc.description.abstractThe aim of this multicenter study was to screen for late-onset Pompe disease in high-risk children with limb-girdle muscle weakness and nonspecific hyperCKemia using the dried blood spot (DBS) test. Seventy-two children from four pediatric neurology departments in Turkey were enrolled in the study: 37 with limb-girdle muscle weakness and 35 with nonspecific hyperCKemia. Acid alpha-glucosidase (GAA) activity Was measured on DBS by tandem mass spectrometry. Six patients tested positively for Pompe disease. In three patients, one with the limb-girdle muscle weakness and two with nonspecific hyperCKemia, this was confirmed by genetic analysis. The overall frequency of late-onset Pompe disease in the study population was 4.2%. The c.1784C>T mutation found in one patient is a new mutation whereas the c.1655T>C mutation detected in the other two patients is not novel. In conclusion, Pompe disease should be suspected in patients with limb-girdle muscle weakness and nonspecific hyperCKemia. The DBS test is a safe and reliable method of diagnosis but must be confirmed by genetic analysis. In patients with a positive DBS test and negative genetic analysis, tissue assay of GAA should be considered. (C) 2016 Published by Elsevier B.V.
dc.description.sponsorshipGenzyme Europe
dc.description.sponsorshipGenzyme Europe provided financial support for the performance of biochemical and genetic analyses.
dc.identifier.doi10.1016/j.nmd.2016.09.001
dc.identifier.endpage800
dc.identifier.issn0960-8966
dc.identifier.issn1873-2364
dc.identifier.issue11
dc.identifier.pmid27666774
dc.identifier.scopusqualityQ1
dc.identifier.startpage796
dc.identifier.urihttps://doi.org/10.1016/j.nmd.2016.09.001
dc.identifier.urihttps://hdl.handle.net/20.500.14730/10524
dc.identifier.volume26
dc.identifier.wosWOS:000387626200012
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherPergamon-Elsevier Science Ltd
dc.relation.ispartofNeuromuscular Disorders
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250302
dc.subjectLate-onset Pompe disease
dc.subjectLimb-girdle muscle weakness
dc.subjectHyperCKemia
dc.subjectDried blood spots
dc.subjectEnzyme replacement therapy
dc.titleThe frequency of late-onset Pompe disease in pediatric patients with limb-girdle muscle weakness and nonspecific hyperCKemia: A multicenter study
dc.typeArticle

Dosyalar

Orijinal paket

Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
10524.pdf
Boyut:
790.16 KB
Biçim:
Adobe Portable Document Format